OVERVIEW

Updates in the pharmacotherapeutic management of familial hypercholesterolemia (FH): present and emerging treatment options is organized by ScientiaCME.

Release Date: Oct 22, 2018
Expiration Date: Oct 22, 2020

Accreditation:
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists:
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-18-038-H01-P. ACPE Accreditation effective 10/30/2018, expires 10/30/2020. This is a Knowledge (K)-type activity.

Description:
In this online CME self-learning program:
Familial hypercholesterolemia (FH), also known as type II hyperlipoproteinemia, is an autosomal dominant disorder characterized by elevated plasma LDL-C levels in the absence of hypertriglyceridemia (or if triglycerides are elevated, they are so independently of FH). There are over 1,600 different mutations associated with FH, and the condition arises from a significant reduction in functional LDL-C receptors (LDL-Rs) – half in the case of heterozygous patients and practically none in the case of homozygous patients – and an attendant reduced rate of LDL-C clearance that predisposes an individual to premature atherosclerotic cardiovascular disease. If the LDL-C levels in a patient are greater than the 95th percentile for age and sex, it is likely that the person has a genetic cause for their hypercholesterolemia and the treatment goal is to prevent cardiovascular disease and cardiovascular related events. Analyses of data from the National Health and Nutrition Examination Survey (NHANES) suggest that the prevalence of FH in the U.S. is about 1 in every 299 persons.

Objectives:
By the end of the session the participant will be able to:
• Describe the pathophysiology and genetics of FH such that they might inform treatment mechanisms
• Describe presently available and emerging treatment options for FH and apply them to patient cases
• Evaluate a FH treatment plan and suggest modifications for improvement